Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-368 + tilsotolimod + nab-paclitaxel + budigalimab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral, Intravenous (other Agents)
01
Overview
This is an investigational combination drug regimen composed of four agents: - **ABBV-368**: a human monoclonal antibody targeting OX40 (TNFRSF4), a co-stimulatory immune checkpoint receptor expressed on T cells, developed to enhance antitumor immune responses. - **Tilsotolimod (IMO-2125)**: a synthetic oligonucleotide agonist of toll-like receptor 9 (TLR9), designed to stimulate innate immune activation and antigen presentation within the tumor microenvironment. - **Nab-paclitaxel**: a nanoparticle albumin-bound formulation of paclitaxel, an established antineoplastic chemotherapy drug that stabilizes microtubules, preventing cell division and inducing apoptosis in cancer cells. - **Budigalimab (ABBV-181)**: a programmed cell death protein 1 (PD-1) inhibitor, functioning as an immune checkpoint inhibitor to block negative regulation of T cells and bolster antitumor immunity. The combination is being evaluated in early-phase clinical studies (phase 1) for advanced or metastatic solid tumors, notably triple negative breast cancer and head and neck squamous cell carcinoma, with the aim of synergistically activating both innate and adaptive arms of the immune system while directly targeting tumor proliferation pathways[1][3].
- Other names
- ABBV-368 + tilsotolimod + nab-paclitaxel + budigalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TLR9 (Toll-like receptor 9)CD28 (Cluster of Differentiation 28)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ABBV-368 + tilsotolimod + nab-paclitaxel + budigalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-368 + tilsotolimod + nab-paclitaxel + budigalimab.